Christopher K. Mirabelli
Managing Director @ HealthCare Ventures
Greater Philadelphia Area, United States
Christopher K. Mirabelli is a Series B investor at HealthCare Ventures in Greater Philadelphia Area focused on Health Care and Biotechnology. Chris Mirabelli joined HealthCare Ventures as a managing director in 2000. Dr. Mirabelli was chairman of the board and chief executive officer of LeukoSite, Inc. from 1993 through 1999, a company in which HealthCare Ventures was the lead investor. He was a co-founder of Isis Pharmaceuticals. He was previously with SmithKline and FrenchLaboratories R&D Division. He is a member of the board of advisors of the Accelerator Fund at Harvard Medical School. He received his Doctor of Philosophy degree in molecular pharmacology from Baylor College of Medicine in Houston, Texas.
- Total investments:
- 11
- Last investment:
- Lead investor:
- 36%
Last updated:
For AI agents: llms.txt
Industries Christopher K. Mirabelli invests in
Stages Christopher K. Mirabelli invests in
Countries Christopher K. Mirabelli invests in
Contacts
| Type | Contact | Validation |
|---|---|---|
| Work email | ||
| Personal email | ||
| Work phone | ||
| Personal phone | ||
| Socials |
Investment Focus
Industry
- Health Care 5 (45%)
- Biotechnology 5 (45%)
- Medical 2 (18%)
- Therapeutics 2 (18%)
- Pharmaceutical 2 (18%)
Stage
- Series B 3 (27%)
- Funding Round 2 (18%)
- Series A 1 (9%)
- Series C 1 (9%)
- Series D 1 (9%)
Investments
| Company | Description | Round | Links |
|---|---|---|---|
| Theraclone Sciences (formerly Spaltudaq) is a Seattle-based discovery-stage biotech focused on the development of novel therapeutic antibodies for the treatment of infectious disease and inflammation. The company's technology harnesses the power of the human immune system to identify naturally evolved monoclonal antibodies from the blood cellsof immunologically relevant human subjects. Recombinant human monoclonal antibodies can be rapidly obtained using our discovery platform and scaled for large-scale industrial production. Such antibody drug candidates may be uniquely important in combating disease and may have potential as therapeutic products that can be administered to a broad patient population. Theraclone is a privately held company with venture investment from ARCH Venture Partners, Canaan Partners, Healthcare Ventures, Amgen Ventures, MPM Capital, and Alexandria Real Estate Investment. | $8M / Series B / Mar 25, 2013 | ||
| DecImmune Therapeutics, Inc., a biotechnology company, manufactures drugs for inflammation and autoimmunity. The company was incorporated in 2001 and is based in Boston, Massachusetts. | Feb 26, 2013 | ||
| DecImmune Therapeutics, Inc., a biotechnology company, manufactures drugs for inflammation and autoimmunity. The company was incorporated in 2001 and is based in Boston, Massachusetts. | $3.2M / Sep 27, 2010 | ||
| Trevena is a privately held clinical stage biopharmaceutical company based in King of Prussia, PA, dedicated to the discovery and development of GPCR biased ligands. Established in late 2007, Trevena was created to translate groundbreaking research on GPCR signaling into a new generation of medicines.They have three programs in development:TRV027, currently in phase 2 clinical testing for the treatment of acute heart failure; TRV130, currently completing phase 1 testing for the intraveneous treatment of postoperative pain; and TRV734, currently in pre-clinical testing for oral treatment of acute and chronic pain. In addition, Trevena has built an early-stage portfolio of drug discovery programs currently in lead optimization.G protein coupled receptors are the targets for more than 30% of all currently marketed therapeutics. There is significant opportunity to improve upon currently marketed GPCR drugs because many have limited efficacy and undesirable adverse effects, which can prevent broader use. Furthermore, many GPCRs are linked to diseases but cannot be translated into medicines because of specific target-related adverse effects. Trevena's biased ligand approach has the potential to address these problems across a wide range of receptors and therapeutic areas. | $35M / Series B / Jul 14, 2010 | ||
| Theraclone Sciences (formerly Spaltudaq) is a Seattle-based discovery-stage biotech focused on the development of novel therapeutic antibodies for the treatment of infectious disease and inflammation. The company's technology harnesses the power of the human immune system to identify naturally evolved monoclonal antibodies from the blood cellsof immunologically relevant human subjects. Recombinant human monoclonal antibodies can be rapidly obtained using our discovery platform and scaled for large-scale industrial production. Such antibody drug candidates may be uniquely important in combating disease and may have potential as therapeutic products that can be administered to a broad patient population. Theraclone is a privately held company with venture investment from ARCH Venture Partners, Canaan Partners, Healthcare Ventures, Amgen Ventures, MPM Capital, and Alexandria Real Estate Investment. | $1.5M / Mar 17, 2010 | ||
| Trevena is a privately held clinical stage biopharmaceutical company based in King of Prussia, PA, dedicated to the discovery and development of GPCR biased ligands. Established in late 2007, Trevena was created to translate groundbreaking research on GPCR signaling into a new generation of medicines.They have three programs in development:TRV027, currently in phase 2 clinical testing for the treatment of acute heart failure; TRV130, currently completing phase 1 testing for the intraveneous treatment of postoperative pain; and TRV734, currently in pre-clinical testing for oral treatment of acute and chronic pain. In addition, Trevena has built an early-stage portfolio of drug discovery programs currently in lead optimization.G protein coupled receptors are the targets for more than 30% of all currently marketed therapeutics. There is significant opportunity to improve upon currently marketed GPCR drugs because many have limited efficacy and undesirable adverse effects, which can prevent broader use. Furthermore, many GPCRs are linked to diseases but cannot be translated into medicines because of specific target-related adverse effects. Trevena's biased ligand approach has the potential to address these problems across a wide range of receptors and therapeutic areas. | $24M / Series A / Mar 01, 2008 | ||
| Theraclone Sciences (formerly Spaltudaq) is a Seattle-based discovery-stage biotech focused on the development of novel therapeutic antibodies for the treatment of infectious disease and inflammation. The company's technology harnesses the power of the human immune system to identify naturally evolved monoclonal antibodies from the blood cellsof immunologically relevant human subjects. Recombinant human monoclonal antibodies can be rapidly obtained using our discovery platform and scaled for large-scale industrial production. Such antibody drug candidates may be uniquely important in combating disease and may have potential as therapeutic products that can be administered to a broad patient population. Theraclone is a privately held company with venture investment from ARCH Venture Partners, Canaan Partners, Healthcare Ventures, Amgen Ventures, MPM Capital, and Alexandria Real Estate Investment. | $29M / Series B / Mar 19, 2007 | ||
| Sequoia Pharmaceuticals is a private, venture-capital funded company founded in 2002. They are engaged in the discovery and development of novel antiviral therapeutics with a focus on combating drug-resistant HIV and HCV. They are also developing pharmacokinetic enhancers to improve the exposure of co-administered therapeutics. | $35M / Series C / Jan 09, 2007 | ||
| Sequoia Pharmaceuticals is a private, venture-capital funded company founded in 2002. They are engaged in the discovery and development of novel antiviral therapeutics with a focus on combating drug-resistant HIV and HCV. They are also developing pharmacokinetic enhancers to improve the exposure of co-administered therapeutics. | $22M / Series B / Mar 20, 2005 | ||
| Progen Pharmaceuticals, Inc. develops pharmaceutical products for the treatment of anti-proliferation and cancer therapeutics. The company's products are also used for the treatment of various diseases, including age-related macular degeneration, infectious diseases, inflammatory diseases, and vascular hyperplasia. Progen Pharmaceuticals, Inc.was founded in 1998 and is headquartered in Redwood City, California. Progen Pharmaceuticals, Inc. was formerly known as CellGate, Inc. As a result of the acquisition of Cellgate, Inc. by Progen Pharmaceuticals Limited, Cellgate's name was changed. As of February 7, 2008, Progen Pharmaceuticals, Inc. operates as a subsidiary of Progen Pharmaceuticals Limited (ASX: PGL). | $43.7M / Series E / Jun 17, 2003 | ||
| See all 11 investments → | |||
Co-Investors
About HealthCare Ventures
HealthCare Ventures is a leading life science venture capital firm investing in pre-clinical or early clinical stage, focused companies with potential to transform patient care.
HealthCare Ventures Contacts
| Name | Phone | Socials | |
|---|---|---|---|
James H. Cavanaugh
Managing Director
|
|||
|
John Littlechild
Managing Director & General Partner
|
|||
|
Christopher K. Mirabelli
Managing Director
|
|||
Douglas E. Onsi
Managing Director
|
|||
Harold Werner
Co-Founder & Managing Director
|
Access 48,091 investors
822 industries, 177 countries. Updated daily. Emails and phones included.
Browse database — It's Free!
Find investors for your startup
Search 48,091 investors by industry and country. Emails and phones included.
Similar Investors
Similar stage
Recommended lists
FAQ
What does Christopher K. Mirabelli invest in?
Christopher K. Mirabelli invests primarily in Health Care, Biotechnology and Medical startups, most often at Series B and Funding Round stage. Most of the 11 investments tracked by Shizune back companies in United States. The Investment Focus section breaks down every industry, stage and country in the portfolio.
How do I contact Christopher K. Mirabelli?
Public channels for Christopher K. Mirabelli include LinkedIn. For a verified work email and phone number, create a free Shizune account — contact data is searched across 20+ sources and validated before delivery, so your outreach lands in the right inbox.
When did Christopher K. Mirabelli last invest?
The most recent investment recorded for Christopher K. Mirabelli closed in Mar 2013. Shizune tracks 11 investments in total for this profile, including round sizes, stages and portfolio companies, all sourced from confirmed public funding rounds and refreshed monthly.
Is Shizune's investor data accurate?
Yes — every stat on this profile is calculated from confirmed public funding rounds monitored across hundreds of sources since 2020. This profile was last refreshed in Sep 2026 and is updated monthly. Spotted something off? Use the “Suggest an edit” link near the top of the page.
Contact your first 100 investors today
Find who invests in your industry, stage, and country. Download investor list with emails in 5 minutes.
Find investors — It's Free!
Continue with Google
Continue with LinkedIn
